Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
24. Juni 2020 16:02 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and...
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
09. Juni 2020 16:02 ET
|
Melinta Therapeutics
Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core Antibiotic Portfolio MORRISTOWN, N. J. , June 09, 2020 (GLOBE NEWSWIRE) --...
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
04. März 2020 16:03 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel...
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
13. Februar 2020 16:02 ET
|
Melinta Therapeutics
Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company...
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
27. Dezember 2019 09:02 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and...
Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019
12. November 2019 17:07 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
24. Oktober 2019 16:02 ET
|
Melinta Therapeutics
~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company Delays Launch of CABP Indication Until Further Visibility Into Liquidity Position ~ ...
Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director
03. September 2019 16:05 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
09. August 2019 07:31 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
09. August 2019 07:30 ET
|
Melinta Therapeutics
~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3 million, Year-Over-Year ~ ...